Chinese researchers describe new dual antagonists of ETA and AT1 receptors

March 20, 2023

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified dual antagonists of endothelin ETA receptor and angiotensin AT1 receptor reported to be useful for the treatment of diabetes, hypertension and renal disorders.

BioWorld Science Cardiovascular Patents

Today's news in brief

BioWorld

BioWorld briefs for Aug. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 13, 2025.

Bayer secures KRAS G12D inhibitor with $1.3B Kumquat deal

BioWorld

With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with...

NME Digest: Q2 2025

BioWorld

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...

Microscopic image of blood cells, chronic myeloid leukemia and thrombocytosis

Scemblix ticks Novartis earnings box; more ahead in CML

BioWorld

Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid...